Immunosenescence: Shaping the Hematological Narrative in the Era of Aging

Yajie Wu, Ji Luo, Jianhao Lin, Shuai Zheng, Yingmiao Wu, Yifei Gao, Jiao Chen, Feifei Che, Ling ZhongAging 2025 · DOI

TL;DR

As our population ages, understanding immunosenescence – the decline of the immune system with age – is crucial for tackling age-related diseases. This review highlights how immunosenescence significantly impacts hematological disorders, increasing disease risk and reducing treatment effectiveness, and calls for novel therapeutic strategies tailored to this aging immune landscape.

What Problem Does This Paper Address?

The paper addresses the growing challenge of age-related diseases, particularly hematological malignancies and non-neoplastic blood disorders, in an increasingly aging global population. While aging is a known risk factor, the specific mechanisms by which the aging immune system contributes to these diseases and hinders treatment efficacy are complex and not fully elucidated. The authors aim to consolidate current knowledge on "immunosenescence" – the physiological and functional deterioration of the immune system with age – and its profound impact on the bone marrow microenvironment, immune cell function, and ultimately, the development, progression, and treatment outcomes of hematological diseases.

Methods

This paper is a comprehensive review, not an experimental study. The authors synthesize existing research from a wide range of peer-reviewed literature. They systematically analyze:

  • Characteristics of immunosenescence: Describing the general decline in immune organ structures and functions.
  • Mechanisms of immunosenescence: Exploring both intrinsic and extrinsic factors contributing to immune aging.
  • Changes in immune cells: Detailing alterations in the number, subpopulations, receptors, and cytokine profiles of various innate and adaptive immune cells (NK cells, dendritic cells, neutrophils, macrophages, T cells, and B cells).
  • Impact on hematological diseases: Connecting these immune changes to the pathogenesis and progression of both neoplastic (e.g., AML, MM) and non-neoplastic (e.g., AIHA, MDS, ITP) hematological disorders.
  • Therapeutic implications: Discussing how immunosenescence affects treatment strategies and proposing future directions.

Datasets

Not discussed in the paper. This is a review article synthesizing existing research.

Key Insights and Ideas

  • Immunosenescence is a double-edged sword: While it increases susceptibility to infections and cancer, it can also, in some contexts, hinder tumor growth by creating a less hospitable environment for aggressive tumors.
  • The bone marrow microenvironment is critical: Immunosenescence disrupts the bone marrow's delicate balance, affecting hematopoietic stem and progenitor cells and interfering with normal blood cell production.
  • Immune cell dysfunction is multifaceted: It's not just about fewer cells; it's about altered function, skewed differentiation (e.g., naive to memory T cells), and impaired communication between immune components.
  • Senescent cells contribute to chronic inflammation: The "Senescence-Associated Secretory Phenotype" (SASP) from senescent cells fuels a low-grade inflammatory state that exacerbates aging and disease.
  • Therapeutic challenges are amplified: Age-related immune changes lead to reduced efficacy of immunotherapies and increased toxicity from conventional treatments, necessitating personalized approaches.

Key Results

The paper doesn't present novel quantitative results but rather synthesizes findings from numerous studies. Key qualitative findings include:

  • T cell imbalance: A shift from naive to memory T cells, reduced CD28 expression, and impaired cytotoxic and proliferative functions.
  • NK cell paradox: An increase in CD56dim NK cells but with attenuated cytotoxicity, alongside reduced expression of activating receptors.
  • Dendritic cell dysfunction: Impaired antigen uptake, processing, and presentation, leading to reduced T cell activation.
  • Neutrophil and macrophage changes: Reduced antimicrobial capacity and altered inflammatory responses.
  • B cell alterations: Decreased antibody affinity and impaired class switch recombination, contributing to reduced vaccine efficacy and increased autoimmunity.
  • Specific disease impacts: Detailed explanations of how these immune changes contribute to the onset, progression, and treatment resistance in conditions like Autoimmune Hemolytic Anemia (AIHA), Myelodysplastic Syndromes (MDS), Immune Thrombocytopenia (ITP), Acute Myeloid Leukemia (AML), and Multiple Myeloma (MM).

Limitations and Future Work

The authors acknowledge that the molecular mechanisms of immunosenescence are still being unraveled. They emphasize the need for:

  • Precise intervention strategies: Focusing on regulating senescent immune cells rather than solely suppressing malignant clones.
  • Individualized treatment plans: Tailoring therapies to the specific immune profile of elderly patients.
  • Dynamic monitoring technologies: Developing tools to track the physical condition and immune status of elderly patients for better treatment guidance.
  • Further research into novel therapeutic targets: Exploring pathways like CD84, Menin, and others related to aging and immune cell function.
  • Senolytics: The potential of drugs that selectively kill senescent cells is highlighted as a promising avenue.

Summary updated

Abstract

Aging has emerged as a critical focus in understanding human diseases. Among many factors in aging, immunosenescence stands out as a significant focus. Immunosenescence is the process of physiological and functional deterioration of the immune system, which consists of organs, cells, immune components and regulatory networks. In hematologic diseases, immunosenescence could affect the bone marrow (BM) microenvironment, resulting in reduced function of hematopoietic stem and progenitor cells, and interfering with normal hematopoiesis. However, how the nature and function of immune cells change during immunosenescence and the effects have not yet been summarized and explored. Therefore, this review reveals the dual role of immunosenescence in increased disease risk and reduced therapeutic efficacy by providing an overview of the characteristics of immunosenescence, the interaction with the mechanisms of development of hematologic diseases, and the impact of immunosenescence on the function of individual immune cells during the diseases. It includes separate descriptions of various immune cells (innate and adaptive immune response cells) involved in immunosenescence, which covers changes in their cell numbers, subpopulations, receptors, cytokine levels, and other aspects. Additionally, it provides an in-depth analysis of how these changes influence the progression of hematologic diseases (both neoplastic and non-neoplastic hematological diseases). Additionally, we explore the impact of senescence on therapeutic strategies and propose treatment programs for elderly patients. With this review, we endeavor to further disclose the mystery of how immunosenescence impacts the onset and progression of hematologic disorders, aiming to offer a scientific footing for devising novel therapeutic approaches for elderly patients and to enhance their prognosis.
BibTeX
@inproceedings{wu2025immunosenescence,
  author = {Yajie Wu and Ji Luo and Jianhao Lin and Shuai Zheng and Yingmiao Wu and Yifei Gao and Jiao Chen and Feifei Che and Ling Zhong},
  title = {{Immunosenescence: Shaping the Hematological Narrative in the Era of Aging}},
  booktitle = {Aging},
  year = {2025},
  doi = {10.14336/ad.2025.0741},
}
Figure